Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
Rangering i aksjer #30359
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
Aksjekurs
$0.25620952
Sist synkronisert: 2024-07-23
Markedsverdi
$17.14M
Endring (1 dag)
10.83%
Endring (1 år)
0.00%
Land
BE
Handel Mithra Pharmaceuticals S.A. (MITRA)

Kategori

Inntekter for Mithra Pharmaceuticals S.A. (MITRA)
Inntekter i 2026 TTM: 0
Ifølge Mithra Pharmaceuticals S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Mithra Pharmaceuticals S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter